Michael Curtis, incoming eGenesis CEO
April 19, 2022 08:30 AM EDTUpdated 10:33 AM
People
Startups

Ex­clu­sive: En route to first xeno­trans­plan­ta­tion tri­al, eGe­n­e­sis taps new CEO weeks af­ter CMO hire

Kyle LaHucik

Senior Reporter

When Michael Cur­tis joined xeno­trans­plan­ta­tion start­up eGe­n­e­sis as pres­i­dent of R&D in late-2020, he knew he’d one day be­come CEO.

He and Paul Sekhri, the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Lil­ly's board un­der­goes more changes; Mer­ck strat­e­gy chief joins Roger Perl­mut­ter at Eikon

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs 

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times